ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,970.84
-1.11%
Dow Jones
42,992.21
-0.77%
US Dollar vs MXN
20.3272
0.00%
Brent Oil
73.44
0.00%
Bitcoin
94,880.01
0.76%
Pepperstone
Advertisement
Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ

  6. Dare Bioscience Inc (DARE) Cotización

Dare Bioscience Inc

Dare Bioscience Inc (DARE)

NASDAQ
3.27
-0.03
(-0.91%)
Cerrado 28 Diciembre 3:00PM
Delayed by 15 minutes
3.265
-0.005
(-0.15%)
Fuera de horario: 6:59PM
Delayed by 15 minutes

Su centro para precios en tiempo real, ideas y debates en vivo

Premium

Estadísticas y detalles clave

Último Precio
3.27
Postura de Compra
3.14
Postura de Venta
3.40
Volume Operado de la Acción
14,780
3.24 Rango del Día 3.315
2.6703 Rango de 52 semanas 7.56
Capitalización de Mercado [m]
28.45M
Precio Anterior
3.30
Precio de Apertura
3.26
Hora
9
@
3.1801
Última hora de negociación
Volumen financiero
US$ 48,286
Precio Promedio Ponderado
3.267
Volumen promedio (3 m)
52,403
Acciones en circulación
8,700,389
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-0.94
Beneficio por acción (BPA)
-3.47
turnover
2.81M
Beneficio neto
-30.16M

Acerca de Dare Bioscience Inc

Dare Bioscience Inc is a biopharmaceutical company committed to advancing innovative products for women's health. The company identifies, develops and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve... Dare Bioscience Inc is a biopharmaceutical company committed to advancing innovative products for women's health. The company identifies, develops and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, primarily in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in advanced clinical development namely, Ovaprene and Sildenafil Cream. Mostrar más

Sector
Pharmaceutical Preparations
Industria
Pharmaceutical Preparations
Sitio web
www.darebioscience.com
Sede
Wilmington, Delaware, USA
Fundado
-
Dare Bioscience Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker DARE. The last closing price for Dare Bioscience was US$3.30. Over the last year, Dare Bioscience shares have traded in a share price range of US$ 2.6703 to US$ 7.56.

Dare Bioscience currently has 8,700,389 shares in issue. The market capitalisation of Dare Bioscience is US$28.71 million. Dare Bioscience has a price to earnings ratio (PE ratio) of -0.94.

DARE Últimas noticias

Más noticias

Form 8-K - Current report

16 Diciembre 2024
Edgar (US Regulatory)

Daré Bioscience Announces Phase 3 Plans for Sildenafil Cream, 3.6%, in the Treatment of Female Sexual Arousal Disorder (FSAD)

FSAD is clinically analogous to erectile dysfunction in men.To date, there are no FDA-approved pharmacological treatments for FSAD; Daré’s Sildenafil Cream has the potential to receive the first...

16 Diciembre 2024
GlobeNewswire Inc.

Daré Bioscience Announces Publication in Sexual Medicine of Positive Findings from Demographic, Behavioral and Medication Use Subgroup Analyses in the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6%

SAN DIEGO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in innovation for the health and wellbeing of women, today announced that additional data from the...

10 Diciembre 2024
GlobeNewswire Inc.

Daré Bioscience Announces $2.5 Million Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1

Daré Bioscience’s DARE-LARC1 Platform Technology has Transformative Potential for Women’s Health as well as in Treating a Broad Range of Diseases Strategic Process Underway to Explore Partnering...

04 Diciembre 2024
GlobeNewswire Inc.

Form EFFECT - Notice of Effectiveness

26 Noviembre 2024
Edgar (US Regulatory)

Form 424B3 - Prospectus [Rule 424(b)(3)]

26 Noviembre 2024
Edgar (US Regulatory)

Form D - Notice of Exempt Offering of Securities

22 Noviembre 2024
Edgar (US Regulatory)

Form S-1 - General form for registration of securities under the Securities Act of 1933

15 Noviembre 2024
Edgar (US Regulatory)

Form 8-K - Current report

14 Noviembre 2024
Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

14 Noviembre 2024
Edgar (US Regulatory)
Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
10.3612.37113402062.913.3452.6703579143.01720282CS
4-0.04-1.20845921453.313.752.6703633393.23273064CS
120.092.830188679253.184.62.6703524033.50436078CS
26-1.3704-29.5319369024.64045.0282.6703729823.82808384CS
52-0.93-22.14285714294.27.562.67033096524.56739203CS
156-21.93-87.023809523825.225.322.670357195813.53772895CS
260-6.45-66.35802469149.7246.22.6703148300119.75174658CS

DARE - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Dare Bioscience?
El precio actual de las acciones de Dare Bioscience es US$ 3.27
¿Cuántas acciones de Dare Bioscience están en circulación?
Dare Bioscience tiene 8,700,389 acciones en circulación
¿Cuál es la capitalización de mercado de Dare Bioscience?
La capitalización de mercado de Dare Bioscience es USD 28.71M
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Dare Bioscience?
Dare Bioscience ha negociado en un rango de US$ 2.6703 a US$ 7.56 durante el último año
¿Cuál es el ratio PE (precio/beneficio) de Dare Bioscience?
El ratio precio/beneficio de Dare Bioscience es -0.94
¿Cuál es el ratio de efectivo a ventas de Dare Bioscience?
El ratio de efectivo a ventas de Dare Bioscience es 10.1
¿Cuál es la moneda de reporte de Dare Bioscience?
Dare Bioscience presenta sus resultados financieros en USD
¿Cuál es el último ingresos anual de Dare Bioscience?
El último ingresos anual de Dare Bioscience es USD 2.81M
¿Cuál es el último beneficio anual de Dare Bioscience?
El último beneficio anual de Dare Bioscience es USD -30.16M
¿Cuál es la dirección registrada de Dare Bioscience?
La dirección registrada de Dare Bioscience es 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808
¿Cuál es la dirección del sitio web de Dare Bioscience?
La dirección del sitio web de Dare Bioscience es www.darebioscience.com
¿En qué sector industrial opera Dare Bioscience?
Dare Bioscience opera en el sector PHARMACEUTICAL PREPARATIONS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
INTZIntrusion Inc
US$ 2.167
(381.56%)
189.59M
AILEiLearningEngines Inc
US$ 0.5932
(267.31%)
563.26M
HUBCWHub Cyber Security Ltd
US$ 0.035
(250.00%)
2.79M
GTIGraphjet Technology
US$ 0.967551
(185.83%)
398.95M
LITMSnow Lake Resources Ltd
US$ 1.61
(82.95%)
131.98M
NEUPNeuphoria Therapeutics Inc
US$ 4.11
(-92.30%)
940.73k
VIRXViracta Therapeutics Inc
US$ 0.16
(-32.49%)
9.47M
PRFXPainReform Ltd
US$ 3.48
(-28.98%)
949.52k
AIREreAlpha Tech Corporation
US$ 2.56
(-28.49%)
8.42M
AVGRAvinger Inc
US$ 0.9721
(-24.05%)
2.16M
AILEiLearningEngines Inc
US$ 0.5932
(267.31%)
557.72M
GTIGraphjet Technology
US$ 0.967551
(185.83%)
398.75M
RGTIRigetti Computing Inc
US$ 17.08
(10.62%)
298.47M
XTIAXTI Aerospace Inc
US$ 0.03935
(-1.63%)
263.01M
QSIQuantum Si Inc
US$ 3.585
(66.74%)
250.36M

DARE Discussion

Ver más
Monksdream Monksdream 4 meses hace
DARE under $4
👍️0
powerbattles powerbattles 7 meses hace
$DARE took the starter! Secure $22 million in the non-dilutive & phase 2 and phase 3 coming $$$
👍️0
harry crumb harry crumb 8 meses hace
Wouldn’t touch this turd with monopoly money until after the r/s, an after the shorting!
👍️0
Awl416 Awl416 8 meses hace
Daré Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women’s Health Product Candidates through Key Catalysts
👍️0
willlbone willlbone 8 meses hace
Vote on R/S.
👍️0
glenn1919 glenn1919 10 meses hace
DARE.................................................https://stockcharts.com/h-sc/ui?s=DARE&p=W&b=5&g=0&id=p86431144783
👍️0
starkd748 starkd748 1 año hace
It's dead lol
👍️0
Monksdream Monksdream 1 año hace
DARE new 52 week low
👍️0
Monksdream Monksdream 1 año hace
DARE new 52 week low
👍️0
Monksdream Monksdream 1 año hace
DARE new 52 week low
👍️0
Monksdream Monksdream 1 año hace
DARE newb52 week low
👍️0
harry crumb harry crumb 2 años hace
Might be a runner in due time
👍️0
nonsequetor nonsequetor 2 años hace
The DARE train has not even left the station... gathering up steam...
👍️0
harry crumb harry crumb 2 años hace
1.00 average, 100k
👍️0
nonsequetor nonsequetor 2 años hace
I hope everyone loaded up Monday...
👍️0
nonsequetor nonsequetor 2 años hace
Monday, Jan 23, is the day...
👍️0
harry crumb harry crumb 2 años hace
Yep agree
👍️0
nonsequetor nonsequetor 2 años hace
If Ovaprene is approved by the FDA, it could be the first monthly non-hormonal contraceptive product for women and a first-in-category option for women seeking a hormone-free, self-administered and monthly birth control method.

https://www.biospace.com/article/releases/dare-bioscience-announces-ide-approval-for-a-single-arm-open-label-pivotal-contraceptive-efficacy-study-of-ovaprene-an-investigational-hormone-free-monthly-intravaginal-contraceptive/
👍️0
nonsequetor nonsequetor 2 años hace
DARE starts revenue soon with its first approved drug, Xaciato and its licensing partner OGN. Q1 or Q2. Milestone payments and double digit royalties.

Additionally, they have up to three products entering Ph3 trials this year: Ovaprene, Sildenafil and HRT-1. Ovaprene for sure is entering Ph3 this summer with NIH and licensing partner $BAYRY.

By 2024, they could have FDA-approved products and $4-$5B market share and exclusivity.
👍️0
nonsequetor nonsequetor 2 años hace
DARE Since Post:
$0.3266
(38.27%)
Then:$0.8534
Now:$1.18

Nice chunk of change so far...
👍️0
harry crumb harry crumb 2 años hace
Mayb, mayb not
👍️0
nonsequetor nonsequetor 2 años hace
Since my call
Jan 03, 2023 9:29 AM

$DARE It has begun...

DARE Since Post:
$0.2566
(30.07%)
Then:$0.8534
Now:$1.11

UM...AH... looks like a winner already...
and it has not even started!

BUT...

I really don't care what negativity others post. I have done my DD, bought low, and will ride the wave to prosperity.

DARE is the real thing, with one of a kind, first in class products, that will turn many heads and make some (who do their own DD) wealthy.

Good fortune to all (except shorts, who bet wrong on this leg up).
👍️0
harry crumb harry crumb 2 años hace
Could be but highly unlikely this becomes a winner
👍️0
nonsequetor nonsequetor 2 años hace
Just a little bit of DD will prove you wrong.
👍️0
harry crumb harry crumb 2 años hace
Dont count on it, this team is not an has not proven anything yet. Could use new management for a change, the stock does note promote a very good company
👍️0
nonsequetor nonsequetor 2 años hace
Hop aboard, this is just the beginning!
👍️0
nonsequetor nonsequetor 2 años hace
DARE up over 30% already this year.
👍️0
nonsequetor nonsequetor 2 años hace
Up 20% in 2 days
👍️0
nonsequetor nonsequetor 2 años hace
UP 10% since yesterday morning.
👍️0
harry crumb harry crumb 2 años hace
This pos needs to be shutdown, what a scam
👍️0
harry crumb harry crumb 2 años hace
Some more news on dare
👍️0
nonsequetor nonsequetor 2 años hace
Daré Bioscience Announces Subject Screening for Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder Complete

https://finance.yahoo.com/news/dar-bioscience-announces-subject-screening-120000980.html
👍️0
harry crumb harry crumb 2 años hace
Some news an this turd is stagnant, very boring company here
👍️0
harry crumb harry crumb 2 años hace
Looks like this pos is going to its 3 yr low of .75 area. What junk!
👍️0
nonsequetor nonsequetor 2 años hace
Q4 will be interesting
👍️0
nonsequetor nonsequetor 2 años hace
WOW!! Nice EOD catapult!!
👍️0
nonsequetor nonsequetor 2 años hace
Another week... another wait...

ZZZZZZZZZZZZZZZZZZZZZZ
👍️0
MattSav MattSav 2 años hace
Good looking week... Hope everyone is enjoying this move upwards... I know we are waiting on 4th quarter for real numbers but wondering if the sentiment here is good enough to through another 10k on shares lol
👍️0
nonsequetor nonsequetor 2 años hace
YES!
👍️0
MattSav MattSav 2 años hace
So should we be excited that they are doing Financials on a Tuesday?
👍️0
MattSav MattSav 2 años hace
So is the corporate presentation today or what I can't open the damn thing
👍️0
nonsequetor nonsequetor 2 años hace
https://www.sec.gov/Archives/edgar/data/0001401914/000149315222019342/ex3-1.htm
👍️0
MattSav MattSav 2 años hace
Anyone find out how the vote went?
👍️0
kruy kruy 2 años hace
You do realize that all the upfront payments and tiered royalties have to be split with the labs that actually invented and produce these products. DARE is only the middleman. These details are all spelled out in the last SEC annual filing.
The best thing that could happen for us shareholders is that some big company that needs a pipeline will buy out this company and its entire complicated business model. Give me $5 a share and I'm happy. Reality wise, I think we could only get $3-$4 because they would need to come to agreements with all the labs that actually engineered all of the products. Either way, I'd be happy with any buyout because the business model as is could take a long time for DARE to break even or show a profit after splitting royalties with all parties involved.
👍️0
nonsequetor nonsequetor 2 años hace
$$$$ Coming in from the Gates!
https://ih.advfn.com/stock-market/NASDAQ/dare-bioscience-DARE/stock-news/88547783/current-report-filing-8-k
👍️0
nonsequetor nonsequetor 3 años hace
This DARE stock will drive a sane man crazy!
👍️0
harry crumb harry crumb 3 años hace
Employee stock incentive plan goes into effect with dare Bod approval. Always good news to have a employee purchase plan for company stock
👍️0
MattSav MattSav 3 años hace
So im new to this stock... What are the opinions of the stock not getting its approval to increase shares?
👍️0
nonsequetor nonsequetor 3 años hace
Just a few more days...
👍️0
nonsequetor nonsequetor 3 años hace
CLINICAL TRIALS RESULTS JUST POSTED
https://www.clinicaltrials.gov/ct2/show/results/NCT03598088?view=results
👍️0

Su Consulta Reciente

NASDAQ
DARE
Dare Bioscience
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados